Leukemia Clinical Trials in Illinois

Showing 181-200 of 814 trials

ACTIVE_NOT_RECRUITINGPHASE1/PHASE244 miles

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

NCT05275478

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.

Locally Advanced Solid Tumor

Tango Therapeutics, Inc.192 participantsStarted Mar 2022

Los Angeles, California, United States • San Francisco, California, United States • Denver, Colorado, United States +17 more locations

COMPLETEDPHASE3112 miles

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

NCT02242942

This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The time on study treatment was approximately one year and the follow-up period will be up to 9 years

Lymphocytic Leukemia, Chronic

Hoffmann-La Roche445 participantsStarted Dec 2014

Gilbert, Arizona, United States • Duarte, California, United States • La Jolla, California, United States +119 more locations

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Leukemia Trials in Other Cities

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Study of AVZO-021 in Patients With Advanced Solid Tumors

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Other Conditions in Illinois